Department of Endocrinology and Metabolic Diseases CCM
Projects
Beobachtungsstudie GET - Growth Hormone Deficiency and Efficacy of Treatment
BIM23A760 - Efficacy and safety of repeated subcutaneous administration of different doses in acromegalic patients.
BPLG-005: Sustained release of human growth hormone in adult GHD
CSOM230C2110
CSOM230D2203 Basket-Studie
Detection of GH-doping
Efficacy of adjuvant Mitotane treatment in prolonging recurrence-free survival in pat.with adrenocortical carcinoma
eF-ment-309643
FIRM-ACT - First Internat. Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment
GH-Doping: Development of a test method to detect GH abuse in sports
Glukosetoleranz in der Akromegalie: Einfluss des Wachstumshormon-Exzesses auf Glukosestoffwechsel und Insulinresist
Hormonal Regulation of Energy Metabolism, Body Weight and Growth. GRK 1208/1
HypoCCS: The Global Hypopituitary Control and Complications Study
International Cooperative Growth Study / International Cooperative Metabolic Study
Lanreotide Autogel + Pegvisomant in Acromegaly
Lysodren-Pharmakokinetik-Studie im Rahmen der FIRM-ACT-Studie
Open-label, multi-center, expanded access study of pasireotide s.c. in pat. with Cushing's disease
OSI-906 in patients with locally advanced or metastatic adrenocortical carcinoma
Pasireotide LAR vs. Octreotide LAR in patients with active acromegaly
Pegvisomant (MES03014/PEGA-0435-005; MES03013/PEGA-0435-003)
PHOENIX-Studie
SIRAC - Sunitnib in refractory adrenocortical carcinoma patients progressing after cytotoxic chemotherapy
The mechanisms of isolated GH deficiency and construction of long acting GH agonists and antagonists
If the list does not contain any entry, the request was executed without results.